Cadila Pharma launches Bempedoic acid under brand name Belmore to treat bad cholesterol
As per published data, more than 30 percent of adults in urban areas and 20 percent in rural areas in the country are suffering from the heart ailment.
New Delhi: Drugmaker, Cadila Pharmaceuticals has recently announced that the company has launched a drug under the brand name Belmore (Bempedoic acid) for the treatment of high LDL-cholesterol.
Bempedoic acid is a one-of-its-kind drug for the treatment of high LDL (low-density lipoprotein) cholesterol, also known as bad cholesterol which can lead to serious life-threatening heart complications due to blockage in blood vessels.
"Belmore (bempedoic acid) provides additional benefits to patients, and all pre-launch studies have established this advantage. Belmore is one more addition to our fast-growing portfolio of indigenous innovations," Cadila Pharmaceuticals CEO for Domestic Prescription Business Jawed Zia said in a statement.
As per published data, more than 30 percent of adults in urban areas and 20 percent in rural areas in the country are suffering from the heart ailment.
Statins are the group of drugs used to control LDL-cholesterol, but in more than 80 percent of the patients, these drugs either do not give optimum control or are not tolerated.
Cadila Pharmaceuticals is an Indian privately-held pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company was founded in 1951 by Indravadan Modi.
Cadila manufactures products ranging from API's-Intermediates, finished formulations, OTC-Food Supplements, Biotechnology Products and pharmaceutical Machinery. Its manufacturing facilities are approved by UK-MHRA, WHO-GMP, USFDA-API, TGA-Australia, and AIFA-Italy.
Next Story
